NBTX vs ONCO vs AGEN vs IMVT vs RCUS

For growth investors, Agenus Inc.

(AGEN) is the stronger pick with 10. 4% revenue growth year-over-year, versus -132. 1% for Nanobiotix S. A. (NBTX). Analysts rate Nanobiotix S. A. (NBTX) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Nanobiotix S.

A. (NBTX) delivered a total return of +197. 1%, compared to -100. 0% for Onconetix, Inc. (ONCO). Over 10 years, the gap is even starker: IMVT returned +190. 9% versus ONCO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Onconetix, Inc.

(ONCO) is the lower-risk stock at 1. 28β versus Agenus Inc. 's 2. 58β — meaning AGEN is approximately 102% more volatile than ONCO relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Agenus Inc.

(AGEN) is pulling ahead at 10. 4% versus -132. 1% for Nanobiotix S. A. (NBTX). On earnings-per-share growth, the picture is similar: Agenus Inc. grew EPS 100. 0% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nanobiotix S.

A. (NBTX) is the more profitable company, earning 586. 9% net margin versus -1721. 0% for Onconetix, Inc. — meaning it keeps 586. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NBTX leads at 589. 1% versus -778. 2% for ONCO. At the gross margin level — before operating expenses — NBTX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AGEN: 91.

9% to $7. 33.

In this comparison, ONCO (34.

1% yield) pays a dividend. NBTX, AGEN, IMVT, RCUS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Onconetix, Inc.

(ONCO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 28), 34. 1% yield). Agenus Inc. (AGEN) carries a higher beta of 2. 58 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ONCO: -100. 0%, AGEN: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NBTX is a small-cap quality compounder stock; ONCO is a small-cap income-oriented stock; AGEN is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock. ONCO pays a dividend while NBTX, AGEN, IMVT, RCUS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.